2017
Retrospective evaluation of toceranib phosphate (Palladia) use in cats with mast cell neoplasia
Berger E, Johannes C, Post G, Rothchild G, Shiu K, Wetzel S, Fox L. Retrospective evaluation of toceranib phosphate (Palladia) use in cats with mast cell neoplasia. Journal Of Feline Medicine And Surgery 2017, 20: 95-102. PMID: 29172873, PMCID: PMC11129263, DOI: 10.1177/1098612x17695898.Peer-Reviewed Original ResearchConceptsMast cell neoplasiaCell neoplasiaAdverse eventsClinical benefitUse of toceranibDuration of therapyPossible clinical benefitFurther prospective studiesMajority of catsVeterinary Internal MedicineHematologic eventsToceranib treatmentGastrointestinal involvementMedian doseMedian durationDose adjustmentTreatment breaksProspective studyConcurrent treatmentAmerican CollegeRetrospective evaluationAnatomic classificationFeline patientsGastrointestinal casesToceranib
2016
Tolerability of toceranib phosphate (Palladia) when used in conjunction with other therapies in 35 cats with feline oral squamous cell carcinoma: 2009–2013
Olmsted G, Farrelly J, Post G, Smith J. Tolerability of toceranib phosphate (Palladia) when used in conjunction with other therapies in 35 cats with feline oral squamous cell carcinoma: 2009–2013. Journal Of Feline Medicine And Surgery 2016, 19: 568-575. PMID: 26951557, PMCID: PMC11128809, DOI: 10.1177/1098612x16638118.Peer-Reviewed Original ResearchConceptsOral squamous cell carcinomaSquamous cell carcinomaToceranib phosphateCell carcinomaTreatment modalitiesFeline oral squamous cell carcinomaMetabolic toxicityNon-steroidal anti-inflammatory drugsCurrent treatment optionsFavorable toxicity profileCommon oral tumorAnti-inflammatory drugsMajority of catsAdditional therapyGastrointestinal toxicityGI toxicityMedian doseSurgical excisionTreatment delayPoor prognosisTreatment optionsOral tumorsDose reductionRadiation therapyToxicity profile
2015
Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study
London C, Gardner H, Mathie T, Stingle N, Portela R, Pennell M, Clifford C, Rosenberg M, Vail D, Williams L, Cronin K, Wilson-Robles H, Borgatti A, Henry C, Bailey D, Locke J, Northrup N, Crawford-Jakubiak M, Gill V, Klein M, Ruslander D, Thamm D, Phillips B, Post G. Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study. PLOS ONE 2015, 10: e0124889. PMID: 25923466, PMCID: PMC4414350, DOI: 10.1371/journal.pone.0124889.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, MetronomicAmputation, SurgicalAnimalsBone NeoplasmsCarboplatinCyclophosphamideDiarrheaDisease-Free SurvivalDog DiseasesDogsDrug Therapy, CombinationFemaleIndolesKaplan-Meier EstimateMaleNeutropeniaOsteosarcomaPiroxicamProspective StudiesPyrrolesRegression AnalysisTreatment OutcomeConceptsDisease-free intervalMedian disease-free intervalCarboplatin chemotherapyMetastatic diseaseOverall survivalControl dogsMaintenance therapyAppendicular osteosarcomaMedical conditionsSurvival rateTherapy-associated adverse eventsGross metastatic diseaseMedian overall survivalOutcome of dogsProspective clinical trialsYear survival rateMulti-institutional studyPiroxicam therapyCyclophosphamide therapyAdverse eventsPatient demographicsSupportive careStudy entryMetronomic treatmentClinical trials
2003
Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.
London CA, Hannah AL, Zadovoskaya R, Chien MB, Kollias-Baker C, Rosenberg M, Downing S, Post G, Boucher J, Shenoy N, Mendel DB, McMahon G, Cherrington JM. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clinical Cancer Research 2003, 9: 2755-68. PMID: 12855656.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsDog DiseasesDogsDose-Response Relationship, DrugEnzyme InhibitorsFemaleIndolesInhibitory Concentration 50MaleModels, ChemicalMutationNeoplasmsProto-Oncogene Proteins c-kitPyrrolesReceptor Protein-Tyrosine KinasesReceptors, Vascular Endothelial Growth FactorTime FactorsTomography, X-Ray ComputedConceptsReceptor tyrosine kinase inhibitorsTyrosine kinase inhibitorsGrowth factor receptorKinase inhibitorsSpontaneous malignanciesSpontaneous tumorsSmall molecule receptor tyrosine kinase inhibitorPhase I dose-escalating studyDose-escalating studyMeasurable objective responseSimilarities of canineVascular endothelial growth factor receptorStandard treatment regimensFactor receptorPhase I trialEndothelial growth factor receptorOverall response rateSoft tissue sarcomasPlatelet-derived growth factor receptorMast cell tumorsVariety of cancersStable diseaseObjective responseOral therapyProgressive disease